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DYSMORPHOPHOBIA WITH BIPOLAR AFFECTIVE 




3 AND SHEKHAR SAXENA
4 
This case report describes the progression of dysmorphophobic symptoms in the dimension of intensity from a normal 
age related concent, to primary dysmorpliophobia, to a somatic delusion during depressive and manic phases of a 
bipolar affective disorder. The depressive episodes were resistant to drug treatment but responded to ECTs. 
JLJysmorphophobia was originally defined as "a 
subjective feeling of ugliness or physical defect which 
the patient feels noticeable to others although his ap-
pearence is within normal limits" (Morselli, 1986). As a 
symptom the feeling may be expressed as a preoccupa-
tion with appearence, an obsession, an overvalued idea 
or frank delusion (Birtchnell, 1988). Thus with the same 
content the symptom may appear in different forms. 
DSM- IIIR recognised 'body dysmorphic disorder' as 
a new diagnosis under the category of somatoform 
disorder and defined it as preoccupation with some 
imagined defect in appearence in normal appearing 
person or an excessive concern about slight physical 
anomaly (APA, 1987). However, when the belief 
reaches delusional certainty with loss of insight, the 
diagnosis is delusional disorder, somatic subtype 
(APA, 1987), Phenomenologically, there may be a 
spectrum along the contirinum of certainty of the belief 
and the presence of insight. Difficulty may arise in 
judging the intensity of the belief in clinical setting 
(Braddock, 1982) and hence, in assigning the diagnosis. 
The following report shows progression of dys-
morphophobic preoccupation into a delusion during 
the depressive and manic episodes of a bipolar disor-
der. Comments are also made on the treatment of such 
a case. 
CASE 
Ms. N, a single professional woman of average 
build and body weight felt since adolescence that her 
breasts were larger than average. She thought that this 
prevented her from being confident and smart. At the 
age of 23 years she was prescribed 
medroxyprogesterone for three months for menstrual 
disturbance. She developed facial hair growth and 
breast enlargement which were mild and not readily 
discernible to others. She began to have preoccupation 
with her appearance and thought that she looked ugly 
because of facial hair and enlarged breasts. Her con-
cern about these slight physical changes was clearly 
excessive and caused personal distress but it had no 
significant effect on her functioning at work or at home. 
After about four months she began feeling un-
happy and hopeless. She developed lack of confidence, 
apprehension in meeting people and generalised disin-
terest in all activities. She had crying spells, frequent 
suicidal idea and once made an abortive attempt by 
trying to ingest mercury. Her sleep was disturbed 
throughout the night and appetite was poor. The 
patient attributed the symptoms to the changes in her 
appearence and requested for surgery to reduce 
breast size. Her belief in these physical defects and the 
effect of these on her appearence had now become 
delusional in intensity. She was treated with imipramine 
75-200 mg/'day for three months without significant 
improvement. At that time, she switched into a phase 
of euphoria, authoritativeness and spontaneous exces-
sice speech lasting for two weeks. However, her belief 
about the physical defects remained unaltered. On 
haloperidol 15 mg/day she went back to the previous 
phase of depression. After further unsuccessful treat-
ment with amitryptiline 175 mg/day and amitryptiline 
with lithium augmentation (lithium 900 mg/day), she 
was given nine modified electroconvulsive therapies, to 
which she responded, albeit slowly. The entire episode 
lasted eight months. While being euthymic she con-
tinued to have the preoccupation with enlarged breasts 
although it was no longer delusional and did not affect 
her functioning any more. She remained in this state 
for three years and was not on any drugs. 
Following her engagement the concern about 
her breast size again become more intense. She started 
going to th bathroom repeatedly to check herself in the 
mirror, trying out brassieres and complaining that none 
actually fitted her well. Her interaction with people 
diminished. She stopped going to work within two 
weeks. She felt sad, often broke into tears and lost 
interest in most routine activities. Her sleep and ap-
petite were also poor. She desired surgery to alter the 
breast size and said that it was not worth living other-
wise. She was initially put on prothiaden 150 mg/day 
without any improvement. It was then changed to 
fluoxotcne 20 mg/day, increased to 40 mg after three 
days and to 60 mg after seven days. After 12 days of 
fluoxetine therapy she rapidly worsened in her depres-
sive state. She became extermcly agitated pacing up 
1 Senior Resident, 2 Pool Officer. 3 Junior Resident. 4 Associate Professor Department of Psychiatry, All-India Institute of Medical Sciences 
New-Delhi, 110029 58  S.N. SENCiUPTA, et al. 
and down the corridors of the ward and crying inces-
santly for help. She said there was hardly any remedy 
for her bodily defect. She repeatedly asked for poison 
expressing intense suicidal ideas. ECT was started at 
that time, fluoxetine was however, continued. She 
showed significant improvement after four ECTs and 
the depression disappeared completely after six ECTs. 
Within a week of the last ECT she could join her work. 
Being maintained on fluoxetine 40 mg/day she 
has remained euthymic during a follow up of two 
months and has been functioning normally. However, 
the dysmorphophobic preoccupation with the breast 
size is continuing and causes some distress but no sig-
nificant disability to her. 
DISCUSSION 
X his patient illustrates the dysmorphophobic 
symptom in the dimension of varying intensity at dif-
ferent periods. She developed concern with her breast 
size during mid adolescence, which was perhaps a nor-
mal, age appropriate phenomenon. After having taken 
medroxyprogesterone which can induce breast enlar-
gement (Jcffcoate, 1975) she developed dysmor-
phophobia as a syndrome characterized by excessive 
concern towards her breast size, causing significant 
distress. The same symptom further developed into a 
clear delusion during episodes of depression and 
mania. This observation is compatible with earlier 
reports by Braddock (1982), Birtchnetl (1988) and Hol-
lander et al. (1989). Dysmorphophobia as asymtom in 
other psychiatric syndromes including depression is 
well known (Barsky, 1989), although earlier it was 
thought to be uncommon (Hay, 1970). If present, it is 
usually delusional (Mckenna, 1984) as this case also 
shows. 
Treatment of dysmorphophobia remains dif-
ficult (Birtchnell, 1988) and a good response to drugs 
is rare (Kcllner, 1989). There is hardly any literature on 
the treatment of depression, when associated with dys-
morphophobia. A recent report (Hollandersal., 1989) 
has suggested that these patients respond well to 
specific serotonin reuptake blockers like fluoxetine. 
! However, this case was resistant to numerous an-
tidepressant drugs including fluoxetine. Her deprees-
sive symptoms actually worsened and suicidal ideation 
increased on fluoxetine. Such paradoxical effect of 
fluoxetine has been reported recently by Teicher et al. 
(1990). This case showed satisfactory response to ECTs 
in both the depressive episodes, the recovery being 
particularly dramatic in the later episode. Along with 
depression, the delusion also disappeared, leaving a 
dysmorphophobic preoccupation of the same charac-
ter and intensity as had existed earlier. This has not 
responded to continued treatment with fluoxetine. 
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